Loomis Sayles & Co. L P Purchases New Shares in Hinge Health Inc. $HNGE

Loomis Sayles & Co. L P bought a new position in shares of Hinge Health Inc. (NYSE:HNGE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 345,143 shares of the company’s stock, valued at approximately $17,861,000. Loomis Sayles & Co. L P owned approximately 0.44% of Hinge Health as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Hinge Health during the second quarter worth $43,840,000. Franklin Resources Inc. acquired a new stake in shares of Hinge Health during the 2nd quarter worth about $28,462,000. American Century Companies Inc. acquired a new stake in shares of Hinge Health during the second quarter valued at about $27,268,000. Ensign Peak Advisors Inc purchased a new stake in Hinge Health in the second quarter valued at approximately $16,172,000. Finally, Norges Bank purchased a new stake in shares of Hinge Health in the 2nd quarter valued at $15,525,000.

Hinge Health Trading Down 2.3%

HNGE opened at $48.91 on Monday. Hinge Health Inc. has a one year low of $33.42 and a one year high of $62.18. The business’s fifty day moving average price is $48.83.

Hinge Health (NYSE:HNGE) last posted its earnings results on Tuesday, November 4th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.18. The business had revenue of $154.21 million for the quarter, compared to analysts’ expectations of $142.44 million. The business’s quarterly revenue was up 53.3% on a year-over-year basis. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hinge Health declared that its Board of Directors has approved a stock repurchase program on Wednesday, November 12th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to buy up to 7.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

HNGE has been the subject of a number of research reports. Canaccord Genuity Group upped their target price on shares of Hinge Health from $61.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Piper Sandler reiterated an “overweight” rating and issued a $71.00 price objective (up previously from $70.00) on shares of Hinge Health in a report on Wednesday, November 5th. Morgan Stanley lifted their price target on shares of Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 23rd. Bank of America lifted their price target on Hinge Health from $42.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Finally, JMP Securities upped their target price on shares of Hinge Health from $58.00 to $65.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hinge Health has an average rating of “Moderate Buy” and an average price target of $59.93.

Insider Buying and Selling

In related news, President James Pursley sold 15,000 shares of Hinge Health stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.57, for a total transaction of $683,550.00. Following the completion of the sale, the president owned 789,902 shares in the company, valued at approximately $35,995,834.14. This trade represents a 1.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Budge sold 44,589 shares of Hinge Health stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $47.47, for a total transaction of $2,116,639.83. Following the sale, the chief financial officer owned 479,878 shares of the company’s stock, valued at approximately $22,779,808.66. This trade represents a 8.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 791,839 shares of company stock worth $32,148,273.

Hinge Health Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.